About NeoTract
NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is to improve the standard of care for patients with Benign Prostatic Hyperplasia (BPH), a broadly underserved market. Our first product is the UroLift® System, a set of minimally invasive devices designed to treat lower urinary tract symptoms (LUTS) due to BPH.
BPH is a common condition that affects over 500 million aging men worldwide.1,2 Causing bothersome, chronic lower urinary tract symptoms, BPH can cause loss of productivity, loss of sleep, depression and decreased quality of life.3 For patients with moderate-severe symptoms, medication is often the first-line therapy.4 However, with side-effects such as sexual dysfunction, dizziness and headaches along with inadequate relief, over one-quarter of patients discontinue medical therapy, often after only three months.5 For these patients, the next alternative is surgery. Most surgical approaches aim to resect or ablate prostate tissue in order to open up the blocked urethra. While effective in opening up the urethra and relieving symptoms, resecting or ablating prostate tissue also induces a healing response and tissue inflammation. As a result, patients have to ‘earn’ their symptom relief after a difficult period of irritative voiding symptoms and catheterization.6,7 Long-term, even the ‘gold standard’ surgery, TURP (transurethral resection of the prostate), can leave patients with unwelcome permanent side-effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation (dry orgasm).6,7
The UroLift System is a set of minimally invasive devices designed to open the urethra directly without the need to resect or ablate prostate tissue. Deployed through the UroLift Delivery Device, permanent UroLift Implants are placed transurethrally to retract the obstructing prostatic lobes while leaving the prostate intact. Clinical results have shown that symptom relief can occur as early as 2 weeks post-procedure while long-term normal sexual function can be preserved. Click here to learn more about UroLift System Treatment.
NeoTract, Inc. was founded in 2004 through the ExploraMed Development, LLC medical device incubator funded by New Enterprise Associates. The Company’s headquarters are in Pleasanton, California, USA.
1. Berry, S.J. et al., J Urology 1984; 132: 474-479
2. U.S. Census Bureau International Database
3. Rosenberg, M.T. et al., Int J Clin Pract, Sept 2007; 61(9): 1535-1546
4. Hutchison, A. et al., Eur Urol 2007 ; 51 : 207-216
5. Verhamme, K.M.C. et al., Eur Urol 2003 ; 44 : 539-545
6. Benign Prostatic Hyperplasia Guideline, Roehrborn, C.G. et al.: Guideline on the Management of Benign
Prostatic Hyperplasia, American Urological Association Education and Research, Inc. 2003
7. Miano, R. et al., Med Sci Monit 2008; 14: RA94